Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM21-1480 in advanced solid tumors
NL-OMON52041Phase 2Withdrawn
- Sponsor
- Numab Therapeutics AG
- Start
- May 2021
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nm21-1480 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC) and 5 more (8 arms), sponsored by Numab Therapeutics AG. Primary endpoints: Best overall response, Objective response rate and 2 more. Planned start May 2021; status: withdrawn.
02
Drugs
nm21-1480
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)squamous cell carcinoma (SCC)ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON52041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52041.